EA201270813A1 - АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ - Google Patents

АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ

Info

Publication number
EA201270813A1
EA201270813A1 EA201270813A EA201270813A EA201270813A1 EA 201270813 A1 EA201270813 A1 EA 201270813A1 EA 201270813 A EA201270813 A EA 201270813A EA 201270813 A EA201270813 A EA 201270813A EA 201270813 A1 EA201270813 A1 EA 201270813A1
Authority
EA
Eurasian Patent Office
Prior art keywords
n3pglu
antibodies
application
amyloid peptide
beta amyloid
Prior art date
Application number
EA201270813A
Other languages
English (en)
Other versions
EA023021B1 (ru
Inventor
Джиронг Лу
Ин Тан
Рональд Брэдли Дематтос
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201270813A1 publication Critical patent/EA201270813A1/ru
Publication of EA023021B1 publication Critical patent/EA023021B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Abstract

Изобретение относится к анти-N3pGlu Аβ антителам или их антигенсвязывающим фрагментам. Кроме того, настоящее изобретение относится к применению анти-N3pGlu Аβ антител или их антигенсвязывающих фрагментов для лечения болезни Альцгеймера.
EA201270813A 2010-08-12 2011-08-09 АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ EA023021B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37302610P 2010-08-12 2010-08-12
PCT/US2011/046994 WO2012021469A1 (en) 2010-08-12 2011-08-09 ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF

Publications (2)

Publication Number Publication Date
EA201270813A1 true EA201270813A1 (ru) 2013-05-30
EA023021B1 EA023021B1 (ru) 2016-04-29

Family

ID=44543826

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270813A EA023021B1 (ru) 2010-08-12 2011-08-09 АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ

Country Status (38)

Country Link
US (2) US8679498B2 (ru)
EP (3) EP2603523B1 (ru)
JP (2) JP5980207B2 (ru)
KR (1) KR101498833B1 (ru)
CN (2) CN103068848B (ru)
AU (1) AU2011289629B2 (ru)
BR (1) BR112013004056B8 (ru)
CA (1) CA2805114C (ru)
CL (1) CL2013000390A1 (ru)
CO (1) CO6670526A2 (ru)
CR (1) CR20130016A (ru)
CY (2) CY1120144T1 (ru)
DK (3) DK3339323T3 (ru)
DO (1) DOP2013000029A (ru)
EA (1) EA023021B1 (ru)
EC (1) ECSP13012436A (ru)
ES (3) ES2764728T3 (ru)
GT (1) GT201300036A (ru)
HK (1) HK1180703A1 (ru)
HR (3) HRP20160151T1 (ru)
HU (2) HUE028678T2 (ru)
IL (2) IL224030B (ru)
LT (2) LT3339323T (ru)
MA (1) MA34461B1 (ru)
ME (3) ME03661B (ru)
MX (2) MX342782B (ru)
MY (2) MY163521A (ru)
NO (1) NO3042917T3 (ru)
NZ (2) NZ606095A (ru)
PE (1) PE20130817A1 (ru)
PL (3) PL2603523T3 (ru)
PT (2) PT3339323T (ru)
RS (3) RS54685B1 (ru)
SG (2) SG187586A1 (ru)
SI (3) SI2603523T1 (ru)
UA (1) UA107600C2 (ru)
WO (1) WO2012021469A1 (ru)
ZA (1) ZA201300437B (ru)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
CN103068848B (zh) * 2010-08-12 2015-11-25 伊莱利利公司 抗N3pGlu淀粉样蛋白BETA肽抗体及其用途
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
WO2015113169A1 (en) * 2014-02-03 2015-08-06 Cnj Holdings, Inc. Humanized beta-amyloid binding molecules and uses thereof
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
EP3166973B1 (en) * 2014-07-10 2020-02-19 Universität Zürich Immune-stimulating monoclonal antibodies against human interleukin-2
TWI599358B (zh) * 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
US20170363645A1 (en) 2014-12-19 2017-12-21 Probiodrug Ag Novel Method for the Detection of pGlu-Abeta Peptides
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
CN106699888B (zh) * 2015-07-28 2020-11-06 上海昀怡健康科技发展有限公司 一种pd-1抗体及其制备方法和应用
IL258036B (en) * 2015-09-23 2022-09-01 Regeneron Pharma Optimized bispecific antibodies against class 3 determinants and their uses
KR20180100224A (ko) 2016-01-11 2018-09-07 노바르티스 아게 인간 인터루킨-2에 대한 면역-자극 인간화 단일클론 항체, 및 이의 융합 단백질
JOP20170004B1 (ar) * 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
AR107783A1 (es) * 2016-03-15 2018-06-06 Lilly Co Eli Terapia de combinación
AR107774A1 (es) 2016-03-16 2018-05-30 Lilly Co Eli Terapia de combinación, método para el tratamiento de la enfermedad de alzheimer
TWI798751B (zh) * 2016-07-01 2023-04-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
WO2018031361A2 (en) * 2016-08-09 2018-02-15 Eli Lilly And Company Combination therapy
WO2018034977A1 (en) 2016-08-18 2018-02-22 Eli Lilly And Company Combination therapy of bace-1 inhibitor and anti-n3pglu abeta antibody
TWI669119B (zh) * 2016-10-21 2019-08-21 美國禮來大藥廠 組合療法
PL3532064T3 (pl) 2016-10-28 2020-11-16 H. Lundbeck A/S Terapie skojarzone obejmujące imidazopirazynony do leczenia zaburzeń psychiatrycznych i/lub poznawczych
MA46621A (fr) 2016-10-28 2021-06-02 H Lundbeck As Traitements combinés comprenant l'administration d'imidazopyrazinones
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
JOP20190247A1 (ar) 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
JP7263320B2 (ja) 2017-08-22 2023-04-24 バイオジェン・エムエイ・インコーポレイテッド 抗ベータアミロイド抗体を含有する医薬組成物
US11634416B2 (en) 2017-12-14 2023-04-25 H. Lundbeck A/S Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
CN111511742B (zh) 2017-12-20 2023-10-27 H.隆德贝克有限公司 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶
AU2020245031A1 (en) * 2019-03-26 2021-10-21 Janssen Pharmaceutica Nv Antibodies to pyroglutamate amyloid-β and uses thereof
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
WO2021257808A2 (en) * 2020-06-17 2021-12-23 Proviva Therapeutics (Hong Kong) Limited Antibodies to fibroblast activation protein and b7h3
MX2023000949A (es) 2020-07-23 2023-02-22 Othair Prothena Ltd Anticuerpos anti-beta-amiloide (abeta).
KR20230061462A (ko) 2020-10-02 2023-05-08 일라이 릴리 앤드 캄파니 단백질 정제 공정에서의 숙주 세포 단백질 함량의 감소 방법
TW202243690A (zh) 2021-01-11 2022-11-16 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
CA3235104A1 (en) 2021-10-22 2023-04-27 Kevin BIGLAN O-glcnacase (oga) inhibitor combination therapy
TW202334210A (zh) 2021-10-29 2023-09-01 美商美國禮來大藥廠 靶向介白素-34之化合物及方法
TW202336034A (zh) 2021-10-29 2023-09-16 美商美國禮來大藥廠 靶向介白素-34之化合物及方法
WO2023076971A1 (en) 2021-10-29 2023-05-04 Eli Lilly Company Compounds and methods targeting interleukin-34
WO2023076970A1 (en) 2021-10-29 2023-05-04 Eli Lilly And Company Compounds and methods targeting interleukin-34
WO2023150483A1 (en) 2022-02-03 2023-08-10 Eli Lilly And Company Regional tau imaging for diagnosing and treating alzheimer's disease
WO2024020470A1 (en) 2022-07-21 2024-01-25 Eli Lilly And Company PHARMACEUTICAL SOLUTIONS OF ANTI-N3pGlu Aβ ANTIBODIES AND USES THEREOF

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7122374B1 (en) * 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
EP1911765A3 (en) 2002-07-24 2008-04-23 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with Beta-Amyloid formation and/or aggregation
WO2005018424A2 (en) * 2003-08-18 2005-03-03 Research Foundation For Mental Hygiene, Inc. Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
CA2538220A1 (en) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Use of antibody
EA009872B1 (ru) * 2004-02-23 2008-04-28 Эли Лилли Энд Компани АНТИ-Aβ АНТИТЕЛА
EA016357B1 (ru) * 2004-07-30 2012-04-30 Ринат Ньюросайенс Корп. Антитела, направленные против бета-амилоидного пептида, и способы их применения
KR101605207B1 (ko) 2006-07-14 2016-03-22 에이씨 이뮨 에스.에이. 아밀로이드 베타에 대해 인간화된 항체
RU2523894C2 (ru) * 2007-04-18 2014-07-27 Янссен Альцгеймер Иммунотерапи Предупреждение и лечение церебральной амилоидной ангиопатии
CA2723995A1 (en) 2008-06-12 2009-12-17 Affiris Ag Compounds for treating symptoms associated with parkinson's disease
WO2010004434A2 (en) 2008-07-09 2010-01-14 University Of Zurich Method of promoting neurogenesis
AU2009273387B9 (en) * 2008-07-21 2015-06-11 Vivoryon Therapeutics N.V. Diagnostic antibody assay
WO2011151076A2 (en) 2010-06-04 2011-12-08 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS
CN103068848B (zh) * 2010-08-12 2015-11-25 伊莱利利公司 抗N3pGlu淀粉样蛋白BETA肽抗体及其用途

Also Published As

Publication number Publication date
SG10201509330XA (en) 2015-12-30
RS59652B1 (sr) 2020-01-31
EA023021B1 (ru) 2016-04-29
MY163521A (en) 2017-09-15
ME02352B (me) 2016-06-20
HUE028678T2 (en) 2016-12-28
CY1122458T1 (el) 2021-01-27
US20140065138A1 (en) 2014-03-06
DK3339323T3 (da) 2020-01-20
IL285226B2 (en) 2023-02-01
US20130142806A1 (en) 2013-06-06
ECSP13012436A (es) 2013-03-28
WO2012021469A1 (en) 2012-02-16
CN103068848B (zh) 2015-11-25
BR112013004056B8 (pt) 2022-10-18
MX342782B (es) 2016-10-12
CA2805114C (en) 2017-12-05
NZ606095A (en) 2014-11-28
ME03661B (me) 2020-07-20
CY1120144T1 (el) 2018-12-12
BR112013004056B1 (pt) 2022-05-17
BR112013004056A2 (pt) 2020-08-04
JP2013536191A (ja) 2013-09-19
PL3042917T3 (pl) 2018-07-31
DK2603523T3 (en) 2016-03-21
SI3339323T1 (sl) 2019-12-31
MY181969A (en) 2021-01-15
MX355268B (es) 2018-04-11
CN105111308B (zh) 2019-03-12
SI2603523T1 (sl) 2016-04-29
ME03032B (me) 2018-10-20
LT3042917T (lt) 2018-05-10
MA34461B1 (fr) 2013-08-01
JP6395755B2 (ja) 2018-09-26
GT201300036A (es) 2014-07-16
AU2011289629A1 (en) 2013-02-14
EP3339323B1 (en) 2019-11-13
JP5980207B2 (ja) 2016-08-31
CN103068848A (zh) 2013-04-24
UA107600C2 (uk) 2015-01-26
KR20130051989A (ko) 2013-05-21
MX2013001716A (es) 2013-10-28
EP2603523B1 (en) 2016-01-27
US8961972B2 (en) 2015-02-24
ES2664128T3 (es) 2018-04-18
IL285226A (en) 2021-09-30
HK1180703A1 (zh) 2013-10-25
CA2805114A1 (en) 2012-02-16
HRP20160151T1 (hr) 2016-03-11
HRP20180616T1 (hr) 2018-07-13
KR101498833B1 (ko) 2015-03-04
SG187586A1 (en) 2013-03-28
ES2564252T3 (es) 2016-03-21
LT3339323T (lt) 2020-02-10
RS54685B1 (en) 2016-08-31
EP3339323A1 (en) 2018-06-27
ZA201300437B (en) 2014-06-25
EP3042917B1 (en) 2018-02-21
CO6670526A2 (es) 2013-05-15
DOP2013000029A (es) 2013-03-15
CL2013000390A1 (es) 2014-03-21
PL3339323T3 (pl) 2020-05-18
CR20130016A (es) 2013-03-21
EP2603523A1 (en) 2013-06-19
SI3042917T1 (en) 2018-04-30
IL285226B (en) 2022-10-01
CN105111308A (zh) 2015-12-02
NO3042917T3 (ru) 2018-07-21
HUE037524T2 (hu) 2018-09-28
AU2011289629B2 (en) 2014-07-03
PT3339323T (pt) 2020-01-14
PE20130817A1 (es) 2013-07-18
US8679498B2 (en) 2014-03-25
NZ626665A (en) 2016-04-29
IL224030B (en) 2022-04-01
HRP20192233T1 (hr) 2020-03-06
PL2603523T3 (pl) 2016-07-29
PT3042917T (pt) 2018-05-02
EP3042917A1 (en) 2016-07-13
RS57026B1 (sr) 2018-05-31
JP2016179985A (ja) 2016-10-13
DK3042917T3 (en) 2018-04-23
ES2764728T3 (es) 2020-06-04

Similar Documents

Publication Publication Date Title
EA201270813A1 (ru) АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ
EA201171388A1 (ru) Гуманизированные антитела, специфичные к протофибриллярной форме бета-амилоидного пептида
AU2018256498A1 (en) Antibodies to amyloid beta
MX356800B (es) Anticuerpo tau humanizado.
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
UA109633C2 (uk) Антитіло людини проти тканинного фактора
EA201492149A8 (ru) St2-антигенсвязывающие белки
EA201391761A1 (ru) Анти-альфа-синуклеинсвязывающие молекулы
EA201291067A1 (ru) Гуманизированные антигенсвязывающие белки к миостатину
PH12013501456A1 (en) Use of anti~amyloid beta antibody
EA201290589A1 (ru) Cd127-связывающие белки
TR201907261T4 (tr) DKK-1 antikorları.
CY1118046T1 (el) Πρωτεϊνες δεσμευσης με αντιγονο ειδικες για το συστατικο ρ αμυλοειδους ορου
EA201990895A1 (ru) Антитела к о1 и варианты их применения
EA201492162A1 (ru) Антитела к трансглютаминазе 2
MX2013002718A (es) Composiciones de anticuerpo anti-vegfr-3.
WO2009120659A3 (en) Human monoclonal antibodies against amyloid beta protein, and their use as therapeutic agents
CY1117265T1 (el) Αντισωματα aνti-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων
TN2013000045A1 (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
UA108207C2 (xx) Високоафінне людське антитіло до людського ангіопоетину-2
TH149802A (th) โปรตีนจับเกาะแอนติเจน
TH133365A (th) แอนติ-N3pGlu อะมัยลอยด์ เบต้าเพปไทด์ แอนติบอดี และการใช้ของมัน
WO2009120657A3 (en) Human monoclonal antibodies against amyloid beta protein, and their use as therapeutic agents

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG MD TJ TM